Literature DB >> 10335493

Potent neuroprotective and antioxidant activity of apomorphine in MPTP and 6-hydroxydopamine induced neurotoxicity.

E Grünblatt1, S Mandel, M Gassen, M B Youdim.   

Abstract

Apomorphine is a potent radical scavenger and iron chelator. In vitro apomorphine acts as a potent iron chelator and radical scavenger with IC50 of 0.3 microM for iron (2.5 microM) induced lipid peroxidation in rat brain mitochondrial preparation, and it inhibits mice striatal MAO-A and MAO-B activities with IC50 values of 93 microM and 241 microM. Apomorphine (1-10 microM) protects rat pheochromocytoma (PC12) cells from 6-hydroxydopamine (150 microM) and H2O2 (0.6 mM) induced cytotoxicity and cell death. The neuroprotective property of (R)-apomorphine, a dopamine D1-D2 receptor agonist, has been studied in the MPTP (N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) model of Parkinson's disease. (R)-apomorphine (5-10 mg/kg, s.c.) pretreatment in C57BL mice, protects against MPTP (24 mg/kg, i.p.) induced loss of nigro-striatal dopamine neurons, as indicated by striatal dopamine content, tyrosine hydroxylase content and tyrosine hydroxylase activity. It is suggested that the neuroprotective effect of (R)-apomorphine against MPTP neurotoxicity derives from its radical scavenging and MAO inhibitory actions and not from its agonistic activity, since the mechanism of MPTP dopaminergic neurotoxicity involves the generation of oxygen radical species induced-oxidative stress.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10335493     DOI: 10.1007/978-3-7091-6369-6_6

Source DB:  PubMed          Journal:  J Neural Transm Suppl        ISSN: 0303-6995


  8 in total

1.  The activation of dopamine D4 receptors inhibits oxidative stress-induced nerve cell death.

Authors:  K Ishige; Q Chen; Y Sagara; D Schubert
Journal:  J Neurosci       Date:  2001-08-15       Impact factor: 6.167

2.  ATH434 Rescues Pre-motor Hyposmia in a Mouse Model of Parkinsonism.

Authors:  Leah C Beauchamp; Xiang M Liu; Laura J Vella; Paul A Adlard; Ashley I Bush; David I Finkelstein; Kevin J Barnham
Journal:  Neurotherapeutics       Date:  2022-09-29       Impact factor: 6.088

Review 3.  Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.

Authors:  Dirk Deleu; Yolande Hanssens; Margaret G Northway
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

4.  Overdosing on iron: Elevated iron and degenerative brain disorders.

Authors:  Santosh R D'Mello; Mark C Kindy
Journal:  Exp Biol Med (Maywood)       Date:  2020-09-02

5.  Dopamine D2 agonists, bromocriptine and quinpirole, increase MPP+ -induced toxicity in PC12 cells.

Authors:  Keith Chiasson; Benoît Daoust; Daniel Levesque; Maria-Grazia Martinoli
Journal:  Neurotox Res       Date:  2006-08       Impact factor: 3.978

6.  Chelators in the treatment of iron accumulation in Parkinson's disease.

Authors:  Ross B Mounsey; Peter Teismann
Journal:  Int J Cell Biol       Date:  2012-06-13

Review 7.  Three Structural Features of Functional Food Components and Herbal Medicine with Amyloid β42 Anti-Aggregation Properties.

Authors:  Kazuma Murakami; Kazuhiro Irie
Journal:  Molecules       Date:  2019-06-05       Impact factor: 4.411

8.  Apomorphine Reduces A53T α-Synuclein-Induced Microglial Reactivity Through Activation of NRF2 Signalling Pathway.

Authors:  Tony Heurtaux; Melanie Kirchmeyer; Eric Koncina; Paul Felten; Lorraine Richart; Oihane Uriarte Huarte; Herve Schohn; Michel Mittelbronn
Journal:  Cell Mol Neurobiol       Date:  2021-08-20       Impact factor: 4.231

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.